|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chon SH, Berlth F, Plum PS, Herbold T,
Alakus H, Kleinert R, Moenig SP, Bruns CJ, Hoelscher AH and Meyer
HJ: Gastric cancer treatment in the world: Germany. Transl
Gastroenterol Hepatol. 2:532017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song Z, Wu Y, Yang J, Yang D and Fang X:
Progress in the treatment of advanced gastric cancer. Tumour Biol.
39:10104283177146262017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jou E and Rajdev L: Current and emerging
therapies in unresectable and recurrent gastric cancer. World J
Gastroenterol. 22:4812–4823. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tong ZJ, Shi NY, Zhang ZJ, Yuan XD and
Hong XM: Expression and prognostic value of HER-2/neu in primary
breast cancer with sentinel lymph node metastasis. Biosci Rep.
37(pii): BSR201701212017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abrahao-Machado LF and Scapulatempo-Neto
C: HER2 testing in gastric cancer: An update. World J
Gastroenterol. 22:4619–4625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hashimoto K, Tsuda H, Koizumi F, Shimizu
C, Yonemori K, Ando M, Kodaira M, Yunokawa M, Fujiwara Y and Tamura
K: Activated PI3K/AKT and MAPK pathways are potential good
prognostic markers in node-positive, triple-negative breast cancer.
Ann Oncol. 25:1973–1979. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shan X, Wen W, Zhu D, Yan T, Cheng W,
Huang Z, Zhang L, Zhang H, Wang T, Zhu W, et al: miR 1296-5p
inhibits the migration and invasion of gastric cancer cells by
repressing ERBB2 expression. PLoS One. 12:e01702982017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mukhopadhyay A, Nieves E, Che FY, Wang J,
Jin L, Murray JW, Gordon K, Angeletti RH and Wolkoff AW: Proteomic
analysis of endocytic vesicles: Rab1a regulates motility of early
endocytic vesicles. J Cell Sci. 124:765–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shimada K, Uzawa K, Kato M, Endo Y, Shiiba
M, Bukawa H, Yokoe H, Seki N and Tanzawa H: Aberrant expression of
RAB1A in human tongue cancer. Br J Cancer. 92:1915–1921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thomas JD, Zhang YJ, Wei YH, Cho JH,
Morris LE, Wang HY and Zheng XF: Rab1A is an mTORC1 activator and a
colorectal oncogene. Cancer Cell. 26:754–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davis NM, Sokolosky M, Stadelman K, Abrams
SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro
A, et al: Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in
breast cancer: Possibilities for therapeutic intervention.
Oncotarget. 5:4603–4650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Webster CP, Smith EF, Bauer CS, Moller A,
Hautbergue GM, Ferraiuolo L, Myszczynska MA, Higginbottom A, Walsh
MJ, Whitworth AJ, et al: The C9orf72 protein interacts with Rab1a
and the ULK1 complex to regulate initiation of autophagy. EMBO J.
35:1656–1676. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu BH, Li XX, Yang Y, Zhang MY, Rao HL,
Wang HY and Zheng XF: Aberrant amino acid signaling promotes growth
and metastasis of hepatocellular carcinomas through Rab1A dependent
activation of mTORC1 by Rab1A. Oncotarget. 6:20813–20828.
2015.PubMed/NCBI
|
|
16
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ouyang W, Xu L, Huang Z, Guo J, Cai J, Gao
X and Wang Z: Role of HER family members in predicting prognoses in
epithelial ovarian cancer: A meta-analysis. Tumori. 101:595–602.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Murray NP, Reyes E, Fuentealba C, Jacob O
and Orellana N: Possible role of HER-2 in the progression of
prostate cancer from primary tumor to androgen independence. Asian
Pac J Cancer Prev. 16:6615–6619. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lordick F, Al-Batran SE, Dietel M, Gaiser
T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas
A, et al: HER2 testing in gastric cancer: Results of a German
expert meeting. J Cancer Res Clin Oncol. 143:835–841. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim EK, Kim KA, Lee CY and Shim HS: The
frequency and clinical impact of HER2 alterations in lung
adenocarcinoma. PLoS One. 12:e01712802017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cormio L, Sanguedolce F, Cormio A,
Massenio P, Pedicillo MC, Cagiano S, Calò G, Pagliarulo V, Carrieri
G and Bufo P: Human epidermal growth factor receptor 2 expression
is more important than Bacillus Calmette Guerin treatment in
predicting the outcome of T1G3 bladder cancer. Oncotarget.
8:25433–25441. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kurokawa Y, Matsuura N, Kimura Y, Adachi
S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN,
Takiguchi S, et al: Multicenter large-scale study of prognostic
impact of HER2 expression in patients with resectable gastric
cancer. Gastric Cancer. 18:691–697. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM,
Wang ZN, Li HQ, Zhang SB and Sun Z: The clinicopathological
parameters and prognostic significance of HER2 expression in
gastric cancer patients: A meta-analysis of literature. World J
Surg Oncol. 15:682017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hutagalung AH and Novick PJ: Role of Rab
GTPases in membrane traffic and cell physiology. Physiol Rev.
91:119–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Winslow AR, Chen CW, Corrochano S,
Acevedo-Arozena A, Gordon DE, Peden AA, Lichtenberg M, Menzies FM,
Ravikumar B, Imarisio S, et al: α-synuclein impairs macroautophagy:
Implications for Parkinson's disease. J Cell Biol. 190:1023–1037.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu X, Fu B, Chen D, Hong Q, Cui J, Li J,
Bai X and Chen X: miR-184 and miR-150 promote renal glomerular
mesangial cell aging by targeting Rab1a and Rab31. Exp Cell Res.
336:192–203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ramírez-Peinado S, Ignashkova TI, van Raam
BJ, Baumann J, Sennott EL, Gendarme M, Lindemann RK, Starnbach MN
and Reiling JH: TRAPPC13 modulates autophagy and the response to
Golgi stress. J Cell Sci. 130:2251–2265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Liu F, Qin X, Huang T, Huang B,
Zhang Y and Jiang B: Expression of Rab1A is upregulated in human
lung cancer and associated with tumor size and T stage. Aging
(Albany NY). 8:2790–2798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wilks ST: Potential of overcoming
resistance to HER2-targeted therapies through the PI3K/Akt/mTOR
pathway. Breast. 24:548–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Beelen K, Hoefnagel LD, Opdam M, Wesseling
J, Sanders J, Vincent AD, van Diest PJ and Linn SC: PI3K/AKT/mTOR
pathway activation in primary and corresponding metastatic breast
tumors after adjuvant endocrine therapy. Int J Cancer.
135:1257–1263. 2014. View Article : Google Scholar : PubMed/NCBI
|
